Prospective Comparative Randomized Clinical Trial of Three Endodontic Retrograde Filling Materials
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 59
- 主要终点
- Rate of remineralization
研究概览
简要总结
This prospective comparative randomized clinical trial compares healing and bony regeneration in patients who received 1 of 3 different retrograde filling materials following microsurgical apicoectomies for the treatment of periapical lesions of endodontic origin.
详细描述
A prospective comparative randomized clinical trial was designed to evaluate the healing and bony regeneration in patients who received 1 of 3 different retrograde filling materials (EndoSequence®, ProRoot® MTA, or Biodentine®) following microsurgical apicoectomies for the treatment of periapical lesions of endodontic origin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult patients, American Society of Anesthesiologists (ASA) classification I and II
- •Any tooth with a single chronic periapical lesion requiring apical microsurgery
- •Informed consent signed prior to surgery
排除标准
- •Background of drug/alcohol abuse
- •Adjacent periapical lesion
- •Periodontal disease
研究组 & 干预措施
Group 1 EndoSequence
The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.
干预措施: EndoSequence (Drug)
Group 2 ProRoot MTA
The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.
干预措施: ProRoot MTA (Drug)
Group 3 Biodentine
The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.
干预措施: Biodentine (Drug)
结局指标
主要结局
Rate of remineralization
时间窗: 6 months
The pace at which new bone is redeposited
次要结局
未报告次要终点